No abstract available
MeSH terms
-
Adolescent
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Filgrastim
-
Granulocyte Colony-Stimulating Factor / adverse effects*
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Immunologic Factors / adverse effects*
-
Immunologic Factors / therapeutic use
-
Intestinal Neoplasms / blood
-
Intestinal Neoplasms / complications*
-
Intestinal Neoplasms / therapy
-
Kidney Diseases / chemically induced*
-
Leukocytosis / chemically induced*
-
Leukocytosis / complications
-
Lymphoma, Large B-Cell, Diffuse / blood
-
Lymphoma, Large B-Cell, Diffuse / complications*
-
Lymphoma, Large B-Cell, Diffuse / therapy
-
Male
-
Neutropenia / chemically induced
-
Neutropenia / prevention & control
-
Prednisolone / administration & dosage
-
Prednisolone / adverse effects
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use
-
Remission Induction
-
Vinca Alkaloids / administration & dosage
-
Vinca Alkaloids / adverse effects
Substances
-
Antibiotics, Antineoplastic
-
Immunologic Factors
-
Recombinant Proteins
-
Vinca Alkaloids
-
Cytarabine
-
Granulocyte Colony-Stimulating Factor
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Prednisolone
-
Filgrastim